Literature DB >> 2872099

Essential immunogens in human pertussis: the role of fimbriae.

N W Preston.   

Abstract

After the decline in pertussis vaccination in Britain from the mid-1970s, isolates possessing agglutinogen 2 (types 1.2.3 and 1.2) have replaced type 1.3 as the predominant serotypes. These agglutinogen-2 strains are fimbriate, and their predominance in non-vaccinated communities may result from enhanced attachment to mucosal cells. However, type 1.3 cells are not fimbriate; and, because agglutinogen 3 is essential in fully effective whole-cell vaccine, a subcellular vaccine prepared from fimbriae alone (agglutinogen 2) would probably be inadequate. The mouse can be killed with type 1 strains, devoid of agglutinogens 2 and 3, and is therefore not a suitable model for ensuring that pertussis vaccine contains these essential immunogens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2872099

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  10 in total

1.  Fimbrial typing of Bordetello pertussis isolates: agglutination with polyclonal and monoclonal antisera.

Authors:  N Guiso; C H von Konig; C Becker; H Hallander
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 2.  The pertussis enigma: reconciling epidemiology, immunology and evolution.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Proc Biol Sci       Date:  2016-01-13       Impact factor: 5.349

3.  Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.

Authors:  Hans O Hallander; Abdolreza Advani; Declan Donnelly; Lennart Gustafsson; Rose-Marie Carlsson
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

4.  Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains.

Authors:  Olga Borisova; Svetlana Yu Kombarova; Nelli S Zakharova; Marjolein van Gent; Vladimir A Aleshkin; Isabella Mazurova; Frits R Mooi
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

5.  Identification and characterization of heparin binding regions of the Fim2 subunit of Bordetella pertussis.

Authors:  C A Geuijen; R J Willems; P Hoogerhout; W C Puijk; R H Meloen; F R Mooi
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

6.  Purification and characterization of serotype 6 fimbriae from Bordetella pertussis and comparison of their properties with serotype 2 fimbriae.

Authors:  J L Cowell; J M Zhang; A Urisu; A Suzuki; A C Steven; T Liu; T Y Liu; C R Manclark
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

7.  Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.

Authors:  Hans Hallander; Abdolreza Advani; Frances Alexander; Lennart Gustafsson; Margaretha Ljungman; Catherine Pratt; Ian Hall; Andrew R Gorringe
Journal:  Clin Vaccine Immunol       Date:  2013-12-04

8.  Prevalence and characterization of pertactin deficient Bordetella pertussis strains in Brazil, a whole-cell vaccine country.

Authors:  Daniela Leite; Carlos Henrique Camargo; Suely Sanae Kashino; Ricardo Polatto; Luciano Moura Martins; Juliana Cristina Pereira; Lucia Pawloski; Maria Lucia Tondella; Rosangela Siqueira de Oliveira; Lourdes Rehder de Andrade Vaz de Lima
Journal:  Vaccine X       Date:  2021-06-07

9.  Effect of vaccination on Bordetella pertussis strains, China.

Authors:  Liu Zhang; Yinghua Xu; Jianhong Zhao; Teemu Kallonen; Shenghui Cui; Yunqiang Xu; Qiming Hou; Fengxiang Li; Junzhi Wang; Qiushui He; Shumin Zhang
Journal:  Emerg Infect Dis       Date:  2010-11       Impact factor: 6.883

10.  Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis.

Authors:  Naser Mohammadpour Dounighi; Mehdi Razzaghi-Abyane; Mojtaba Nofeli; Hossein Zolfagharian; Fereshteh Shahcheraghi
Journal:  Jundishapur J Microbiol       Date:  2016-07-09       Impact factor: 0.747

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.